8-K

0001683168-24-004619.txt : 20240702 0001683168-24-004619.hdr.sgml : 20240702 20240702170010 ACCESSION NUMBER: 0001683168-24-004619 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240701 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240702 DATE AS OF CHANGE: 20240702 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Phio Pharmaceuticals Corp. CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36304 FILM NUMBER: 241096677 BUSINESS ADDRESS: STREET 1: 11 APEX DRIVE, SUITE 300A STREET 2: PMB 2006 CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 11 APEX DRIVE, SUITE 300A STREET 2: PMB 2006 CITY: MARLBOROUGH STATE: MA ZIP: 01752 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20111019 8-K 1 phio_8k.htm FORM 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 1, 2024

PHIO PHARMACEUTICALS CORP.

(Exact name of registrant as specified in its charter)

Delaware		001-36304		45-3215903
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

11 Apex Drive, Suite 300A, PMB 2006
Marlborough, Massachusetts	01752
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (508) 767-3861

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s):		Name of each exchange on which registered:
Common Stock, par value $0.0001 per share		PHIO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.03 Material Modification to Rights of Security Holders.

To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defined herein) contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

At the Annual Meeting of Stockholders of Phio Pharmaceuticals Corp. (“the Company”) held on June 17, 2024, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to implement a reverse stock split of the Company’s common stock, par value $0.0001 per share, with the ratio to be determined by the Board of Directors (the “Board”) of the Company, within a range of not less than 1-for-2 or greater than 1-for-9. Subsequently on June 25, 2024, the Board determined to fix the ratio for the reverse stock split at 1-for-9. Thereafter, on July 1, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement the 1-for-9 reverse split of its common stock (the “Reverse Stock Split”). The Reverse Stock Split will be effective as of 12:01 a.m. (Eastern Time) on July 5, 2024, and the Company’s common stock will begin trading on The Nasdaq Capital Market on a post-split basis on July 5, 2024.

As a result of the Reverse Stock Split, every nine (9) shares of the Company’s issued and outstanding common stock, par value $0.0001, will be converted into one (1) share of common stock, par value $0.0001, reducing the number of issued and outstanding shares of the Company’s common stock from approximately 4.6 million shares to approximately 0.5 million shares. The Company’s transfer agent, Computershare Trust Company, N. A. (“Computershare”), will provide instructions to stockholders of record regarding the process for exchanging shares.

Because the Certificate of Amendment did not reduce the number of authorized shares of the Company’s common stock, the effect of the Certificate of Amendment and the Reverse Stock Split is to increase the number of shares of common stock available for issuance relative to the number of shares issued and outstanding. The Reverse Stock Split did not alter the par value of the Company’s common stock or modify any voting rights or other terms of the common stock.

No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional shares because they hold a number of pre-Reverse Stock Split shares of the Company’s common stock not evenly divisible by nine (9), will, in lieu of a fractional share, be entitled, upon surrender to the exchange agent of certificate(s) representing their pre-split shares or upon conversion of their shares held in book-entry, to receive a cash payment equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing price per share (as adjusted to reflect the Reverse Stock Split) of the Company’s common stock as reported by The Nasdaq Capital Market on the last trading day prior to the date on which the Reverse Stock Split becomes effective.

Computershare will be issuing all of the post-split shares through their paperless Direct Registration System (“DRS”), also known as “book-entry form”.

Computershare will hold the shares in an account set up for the stockholder.

All book-entry or other electronic positions representing issued and outstanding shares of the Company’s common stock will be automatically adjusted. Those stockholders holding common stock in “street name” will receive instructions from their brokers.

In addition, pursuant to their terms, a proportionate adjustment will be made to the per share exercise price and number of shares issuable under all of the Company’s outstanding equity awards and warrants to purchase shares of common stock, and the number of shares authorized and reserved for issuance pursuant to the Company’s equity incentive plan and employee stock purchase plan will be reduced proportionately.

After the Reverse Stock Split, the trading symbol for the Company’s common stock will continue to be “PHIO.” The new CUSIP number for the Company’s common stock is 71880W501.

The above description of the Certificate of Amendment and the Reverse Stock Split is a summary of the material terms thereof and is qualified in its entirety by reference to the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1, as filed with the Secretary of State of the State of Delaware on July 1, 2024.

2

Item 8.01 Other Events.

On July 2, 2024, the Company issued a press release relating to the matters described in Item 5.03 above. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Number		Description
3.1		Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp., filed with the Delaware Secretary of State on July 1, 2024
99.1		Press Release issued by the Company on July 2, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				PHIO PHARMACEUTICALS CORP.


Date: July 2, 2024				By:	/s/ Robert Bitterman
					Robert Bitterman President & Chief Executive Officer

4

EX-3.1 2 phio_ex0301.htm CERTIFICATE OF AMENDMENT

Exhibit 3.1

CERTIFICATE OF AMENDMENT TO THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF

PHIO PHARMACEUTICALS CORP.

Phio Pharmaceuticals Corp. (the “Corporation”), a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”), hereby certifies as follows:

FIRST:		That the Board of Directors of the Corporation has duly adopted resolutions authorizing the Corporation to execute and file with the Secretary of State of the State of Delaware this Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended (this “Amendment”) to combine each nine (9) outstanding shares of the Corporation’s Common Stock, par value $0.0001 per share (the “Common Stock”), into one (1) validly issued, fully paid and non-assessable share of Common Stock.

SECOND:		That this Amendment was duly adopted in accordance with the terms of the Amended and Restated Certificate of Incorporation, as amended, and the provisions of the Delaware General Corporation Law by the Board of Directors and stockholders of the Corporation.

THIRD:		That upon the effectiveness of this Amendment, the Amended and Restated Certificate of Incorporation, as amended, is hereby amended such that subsection (a) of ARTICLE IV is amended and restated in its entirety to read as set forth below, with no changes to be made to the subsequent sections of ARTICLE IV: (a) Authorized Shares. The total number of shares of stock which the Corporation shall have authority to issue is 110,000,000 shares, consisting of 100,000,000 shares of Common Stock, par value $0.0001 per share (“Common Stock”) and 10,000,000 shares of Preferred Stock, par value $0.0001 per share (“Preferred Stock”). Upon the effectiveness of this Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Corporation, each nine (9) of the Corporation’s Common Stock issued and outstanding at such time shall, automatically and without any further action on the part of the Corporation or the holder thereof, be combined into one (1) validly issued, fully paid and non-assessable share of Common Stock (the “Reverse Stock Split”). The par value of the Common Stock following the Reverse Stock Split shall remain $0.0001 per share. No fractional shares shall be issued, and, in lieu thereof, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock, as determined by the Board of Directors. Each certificate that immediately prior to the Effective Time represented shares of Common Stock (an “Old Certificate”) shall thereafter represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above.

FOURTH:		This Amendment shall be effective as of July 5, 2024, at 12:01 a.m., Eastern Time (the “Effective Time”).

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to the Amended and Restated Certificate of Incorporation to be executed by Robert J. Bitterman, President and Chief Executive Officer of the Corporation, this 1st day of July, 2024.

	PHIO PHARMACEUTICALS CORP.


	By:	/s/ Robert J. Bitterman
		Name: Robert J. Bitterman
		Title: President and Chief Executive Officer

EX-99.1 3 phio_ex9901.htm PRESS RELEASE ISSUED BY THE COMPANY ON JULY 2, 2024

Exhibit 99.1

Phio Pharmaceuticals Announces Reverse Stock Split

MARLBOROUGH, Mass. (Newsfile Corp. – July 2, 2024) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the “Company”), a clinical stage biotechnology company whose proprietary INTASYL^® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-9. The reverse stock split will become effective at 12:01 a.m. Eastern Time on July 5, 2024 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on July 5, 2024 under the Company’s existing trading symbol, “PHIO.” At such time, the Company’s common stock will also commence trading with a new CUSIP number, 71880W501.

The reverse stock split is being implemented to increase the per share trading price of the Company’s common stock, for the purpose of ensuring a share price high enough to comply with the minimum $1.00 bid price requirement for continued listing on The Nasdaq Capital Market.

At the effective time of the reverse stock split, every nine (9) shares of the Company’s common stock issued and outstanding will be combined into one (1) share of common stock issued and outstanding, with no change to the par value of $0.0001 per share. This will reduce the Company’s outstanding common stock from approximately 4.6 million shares to approximately 0.5 million shares. No fractional shares of common stock will be issued as a result of the reverse stock split. Instead, stockholders of the Company’s common stock will receive a cash payment in lieu of any fractional shares to which they would otherwise be entitled. The shares of common stock underlying the Company’s outstanding equity awards and warrants will also be adjusted accordingly. The reverse stock split affects all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s common stock, except for adjustments that may result from the treatment of fractional shares.

The Company has retained its transfer agent, Computershare Trust Company, N.A. (“Computershare”), to act as its exchange agent for the reverse stock split. Stockholders with shares held in certificate form will receive from Computershare instructions regarding the exchange of their certificates. Stockholders that hold shares in book-entry form or hold their shares in brokerage accounts are not required to take any action and will see the impact of the reverse stock split reflected in their accounts, subject to brokers’ particular processes. Beneficial holders of the Company’s common stock are encouraged to contact their bank, broker, custodian or other nominee with questions regarding procedures for processing the reverse stock split.

Additional information regarding the reverse stock split is available in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on May 8, 2024 by the Company.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL^® RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.

For additional information, visit the Company’s website, www.phiopharma.com.

1

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "intend," "believe," "anticipate," "indicate," "plan," "expect," "suggest," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could," “continue,” or the negative of these terms or other similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These forward-looking statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Examples of forward-looking statements include statements regarding compliance with the minimum bid price requirement and other applicable Nasdaq continued listing standards and the effect of the reverse stock split, including the estimated number of shares of common stock outstanding after effecting the reverse stock split. Some factors that may cause the Company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. The Company does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Contact:

Phio Pharmaceuticals Corp.

ir@phiopharma.com

PR Contact
Michael Adams
Bridge View Media

adams@bridgeviewmedia.com

2

EX-101.SCH 4 phio-20240701.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 phio-20240701_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 phio-20240701_pre.xml XBRL PRESENTATION FILE GRAPHIC 7 image_001.jpg GRAPHIC begin 644 image_001.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover	Jul. 01, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jul. 01, 2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-36304
Entity Registrant Name	PHIO PHARMACEUTICALS CORP.
Entity Central Index Key	0001533040
Entity Tax Identification Number	45-3215903
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	11 Apex Drive
Entity Address, Address Line Two	Suite 300A, PMB 2006
Entity Address, City or Town	Marlborough
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01752
City Area Code	508
Local Phone Number	767-3861
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	PHIO
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://phiopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports phio-20240701.xsd phio-20240701_lab.xml phio-20240701_pre.xml phio_8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "phio_8k.htm": { "nsprefix": "PHIO", "nsuri": "http://phiopharma.com/20240701", "dts": { "schema": { "local": [ "phio-20240701.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "phio-20240701_lab.xml" ] }, "presentationLink": { "local": [ "phio-20240701_pre.xml" ] }, "inline": { "local": [ "phio_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://phiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-07-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "phio_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-07-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "phio_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001683168-24-004619-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-004619-xbrl.zip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end XML 18 phio_8k_htm.xml IDEA: XBRL DOCUMENT 0001533040 2024-07-01 2024-07-01 iso4217:USD shares iso4217:USD shares false --12-31 0001533040 8-K 2024-07-01 PHIO PHARMACEUTICALS CORP. DE 001-36304 45-3215903 11 Apex Drive Suite 300A, PMB 2006 Marlborough MA 01752 508 767-3861 false false false false Common Stock, par value $0.0001 per share PHIO NASDAQ false